Long-term Study to Evaluate Safety and Persistence of GF-CART01
NCT06985576 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 18
Last updated 2025-12-18
Summary
The goal of this observational study is to learn about the long-term safety of GF-CART01 after cell infusion up to 15 years.
Conditions
- DLBCL - Diffuse Large B Cell Lymphoma
- Follicular Lymphoma (FL)
- Primary Mediastinal Large B-Cell Lymphoma
- High Grade B Cell Lymphoma
Sponsors & Collaborators
-
GenomeFrontier Therapeutics TW Co., Ltd.
lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-05-31
- Primary Completion
- 2041-05-31
- Completion
- 2041-05-31
Countries
- Taiwan
Study Locations
More Related Trials
-
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
NCT05909527 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
NCT03146533 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
NCT04595162 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
NCT05948033 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL
NCT05554575 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
NCT03825718 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
NCT03101709 ·Status: UNKNOWN ·Phase: PHASE1
-
Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies
NCT02813837 ·Status: UNKNOWN ·Phase: NA
-
Long-term Follow-up of Subjects Treated With CAR T Cells
NCT05024175 ·Status: RECRUITING
-
CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
NCT06567366 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma
NCT07093086 ·Status: WITHDRAWN ·Phase: PHASE1
-
CD30 CAR-T in the Treatment of CD30 Positive Lymphoma
NCT07048353 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
NCT03825731 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Long-term Follow-up Study of Patients Receiving CAR-T Cells
NCT03375619 ·Status: RECRUITING
-
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
NCT05836896 ·Status: RECRUITING ·Phase: PHASE1
-
CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas
NCT03383965 ·Status: RECRUITING ·Phase: PHASE1
-
CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT
NCT03685786 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
NCT03690310 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
NCT05715606 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
CAR-T Cells in the Treatment of Malignant Hematological Tumors
NCT05619861 ·Status: UNKNOWN ·Phase: NA
-
Bio-CAR-T BS Study
NCT05366569 ·Status: RECRUITING
-
Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma
NCT06987916 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
NCT06911710 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19
NCT01864889 ·Status: UNKNOWN ·Phase: NA
-
CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors
NCT06647329 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1